Study S000615

A Multicenter, Randomized, Double-blinded, Placebo-controlled Phase III Trial to Evaluate the Efficacy and Safety of Liraglutide on Body Weight Loss in Obese and Overweight Patients

ClinicalTrials.gov record Study Protocol and Statistical Analysis Plan (PDF)

Registration

Registration: NCT04605861
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: COMPLETED
Enrollment: 414
Start: 2020-08-18
Primary completion: 2022-12-31
Lead sponsor: Shanghai Zhongshan Hospital
Conditions: Obese; Overweight
Interventions: DRUG:Liraglutide; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

The percentage of body weight loss [through study completion, an average of 32 weeks]
The proportion of body weight loss ≥ 5 percent [through study completion, an average of 32 weeks]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0017898	Liraglutide for Children 6 to <12 Years of Age with Obesity. Malozowski S, The New England journal of medicine	2025	Other trial	PMID 40334165 DOI	cites ClinicalTrials.gov:NCT04605861